RxDoctor Payments Data

Janet Usher

Adult Health · Nashville, TNNPI 1750735528

Payments from drug & device makers

$2,162in general payments, 2019–2025

Across 26 payments — averaging $83.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$535
  • Coloplast$303
  • Endo USA, Inc.$210
  • Boston Scientific$165
  • Astellas Pharma US Inc$160
  • Seagen Inc.$123
  • plus $666 from 7 others

What the payments were for

  • Food & beverage$2,10097%
  • Education$623%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,162 in reported general payments places this provider in the 75th percentile of 352 adult health providers in Tennessee.

See all adult health providers in Tennessee

Medicare billing

Part B allowed, 2024
$64,503
Medicare patients
440
Services billed
1,249

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron96$105,347
MyrbetriqMirabegron90$86,668
Trospium Chloride137$10,164
Tamsulosin Hcl445$7,381
Trospium Chloride ErTrospium Chloride22$2,854
Solifenacin Succinate24$2,735
Finasteride218$2,633
Alfuzosin Hcl ErAlfuzosin Hcl98$2,156
Tadalafil12$1,804
Oxybutynin Chloride ErOxybutynin Chloride20$504
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst16$433
Terazosin Hcl18$404
Doxazosin Mesylate18$354
Ciprofloxacin Hcl39$283
Testosterone Cypionate12$180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$123$105,34796 claims
Astellas Pharma US IncMyrbetriq$160$86,66890 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 352 adult health providers in Tennessee.

Other adult health in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →